Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients.

Simple item page
dc.contributor.authorHanvivadhanakul, Punchongen_US
dc.contributor.authorAkkasilpa, Somchaien_US
dc.contributor.authorDeesomchok, Utisen_US
dc.date.accessioned2009-05-27T21:51:15Z
dc.date.available2009-05-27T21:51:15Z
dc.date.issued2002-06-22en_US
dc.descriptionChotmaihet Thangphaet.en_US
dc.description.abstractThis study was aimed to evaluate the efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients with normal renal function (serum creatinine < or = 1.5). The authors conducted a crossover study consisting of two four-week treatment periods of allopurinol 300 mg/day and benzbromarone 100 mg/day separated by a four-week washout period. Fourteen patients with mean age and duration of hyperuricemia of 60.78 +/- 8.62 and 6.93 +/- 3.69 years, respectively, were recruited and all completed our study protocol. This study was a crossover design consisting of two four-week treatments of allopurinol and benzbromarone separated by a four-week washout period. The serum uric acid level was reduced from 9.89 +/- 1.43 mg/dl to 5.52 +/- 0.83 mg/dl and from 9.53 +/- 1.48 to 4.05 +/- 0.87 mg/dl by allopurinol and benzbromarone, respectively. The efficacy of benzbromarone in lowering serum uric acid level was significantly superior to allopurinol (p=0.005). No patient reported clinical side effects during treatment with either drug. In conclusion, the authors have shown that benzbromarone is more effective than allopurinol in the reduction of serum uric acid levels in hyperuricemic patients with normal renal function.en_US
dc.description.affiliationDepartment of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.en_US
dc.identifier.citationHanvivadhanakul P, Akkasilpa S, Deesomchok U. Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients. Journal of the Medical Association of Thailand. 2002 Jun; 85 Suppl 1(): S40-7en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/45518
dc.language.isoengen_US
dc.source.urihttps://www.mat.or.th/journal/all.phpen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAllopurinol --administration & dosageen_US
dc.subject.meshBenzbromarone --administration & dosageen_US
dc.subject.meshCross-Over Studiesen_US
dc.subject.meshDose-Response Relationship, Drugen_US
dc.subject.meshDrug Administration Scheduleen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshGout --blooden_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshProbabilityen_US
dc.subject.meshStatistics, Nonparametricen_US
dc.subject.meshTreatment Outcomeen_US
dc.subject.meshUric Acid --blooden_US
dc.subject.meshUricosuric Agents --administration & dosageen_US
dc.subject.meshUrinalysisen_US
dc.titleEfficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients.en_US
dc.typeClinical Trialen_US
dc.typeComparative Studyen_US
dc.typeControlled Clinical Trialen_US
dc.typeJournal Articleen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Journal of the Medical Association of Thailand